CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia

The New England Journal of Medicine·Dec 7

This story is reported by The New England Journal of Medicine. Read what other outlets are saying below, then open the original report for full details.

Full coverage

1

CRISPR-Cas9-Mediated Gene Editing in Hematological Disorders: Advancing Translational and Clinical Applications

Cureus·May 11

2

Gene therapy for sickle cell and β-thalassemia works by disrupting three-dimensional genome structure

St. Jude Children's Research Hospital·Nov 5

3

Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease

The New England Journal of Medicine·Apr 2

4

In 2023, the UK was the first country to approve a Crispr therapy. How’s it doing?

Chemistry World·Jan 29

5

CRISPR/Cas-edited iPSCs and mesenchymal stem cells: a concise review of their potential in thalassemia therapy

Frontiers·Sep 3

6

Emerging Therapies for Sickle Cell Disease: From Symptom Management to Curative Gene Therapy

Cureus·Oct 21

7

Sickle cell and beta thalassemia: what are the treatment options and challenges?

UK Parliament·Nov 25

8

Novel genetic therapies for sickle cell disease and β-thalassemia

Contemporary Pediatrics·Jun 5